New radioactive therapy targets mysterious cancers
NCT ID NCT07434180
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a new radioactive drug, Lu-177 FAP-2286, in 20 patients with cancer of unknown primary (CUP). The drug targets a protein found on cells near tumors, delivering radiation directly to the cancer. The main goal is to see if the treatment can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lu-177 FAP-2286 (a radioactive drug that targets cancer cells)
What this could lead to
If successful, this could offer a new treatment option for patients with cancer of unknown primary, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment involves radiation, which can cause side effects, and it is not yet known if it will be effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF UNKNOWN PRIMARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••